AP1282A - HIV envelope polypeptides and vaccine. - Google Patents

HIV envelope polypeptides and vaccine. Download PDF

Info

Publication number
AP1282A
AP1282A APAP/P/1999/001432A AP9901432A AP1282A AP 1282 A AP1282 A AP 1282A AP 9901432 A AP9901432 A AP 9901432A AP 1282 A AP1282 A AP 1282A
Authority
AP
ARIPO
Prior art keywords
thr
asn
aat
lys
val
Prior art date
Application number
APAP/P/1999/001432A
Other languages
English (en)
Other versions
AP9901432A0 (en
Inventor
Philip W Berman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AP9901432A0 publication Critical patent/AP9901432A0/xx
Application granted granted Critical
Publication of AP1282A publication Critical patent/AP1282A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
APAP/P/1999/001432A 1996-07-08 1997-07-03 HIV envelope polypeptides and vaccine. AP1282A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67673796A 1996-07-08 1996-07-08
PCT/US1997/009690 WO1998001564A1 (en) 1996-07-08 1997-07-03 Hiv envelope polypeptides and vaccine

Publications (2)

Publication Number Publication Date
AP9901432A0 AP9901432A0 (en) 1999-03-31
AP1282A true AP1282A (en) 2004-06-09

Family

ID=24715764

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001432A AP1282A (en) 1996-07-08 1997-07-03 HIV envelope polypeptides and vaccine.

Country Status (13)

Country Link
US (1) US6090392A (ref)
EP (1) EP0942988A1 (ref)
JP (1) JP2000515368A (ref)
AP (1) AP1282A (ref)
AU (1) AU727107B2 (ref)
CA (1) CA2259965A1 (ref)
ID (1) ID17767A (ref)
IL (2) IL127701A0 (ref)
NZ (1) NZ333500A (ref)
OA (1) OA10954A (ref)
TW (1) TWI221846B (ref)
WO (1) WO1998001564A1 (ref)
ZA (1) ZA975889B (ref)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
IL150961A0 (en) 2000-02-04 2003-02-12 Univ Duke Human immunodeficiency virus vaccine
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
AUPS065002A0 (en) 2002-02-20 2002-03-14 Immunaid Pty Ltd Strategy for retroviral immunotherapy
AU2001291050A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
AU2001291049A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
WO2002064154A2 (en) * 2001-02-15 2002-08-22 The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services Methods and compositions for inhibiting hiv-coreceptor interactions
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
AU2003298912B2 (en) * 2002-12-03 2011-06-02 Advanced Bioscience Laboratories, Inc. Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
WO2004110384A2 (en) * 2003-06-12 2004-12-23 Vaxgen, Inc. Hiv-1 envelope glycoproteins having unusual disulfide structure
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
DE602004030369D1 (de) * 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
ATE546733T1 (de) * 2004-09-08 2012-03-15 Immunaid Pty Ltd Therapiestrategie zur behandlung von autoimmunkrankheiten und degenerativen erkrankungen
AU2005284922B2 (en) * 2004-09-14 2010-12-23 Coimmune, Inc. Strain independent amplification of pathogens and vaccines thereto
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2009017743A2 (en) 2007-07-30 2009-02-05 Argos Therapeutics, Inc. Improved primers and probes for the amplification and detection of hiv gag, rev and nef polynucleotides
KR101701198B1 (ko) 2008-06-19 2017-02-01 배리에이션 바이오테크놀로지스 아이엔씨. 인플루엔자를 치료하기 위한 조성물 및 방법
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
EP0339504A3 (en) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160
WO1991004273A2 (en) * 1989-09-22 1991-04-04 Idec Pharmaceuticals Corp. Novel peptides associated with the cd4 binding region of gp120 and their methods of use
CA2078545A1 (en) * 1990-04-03 1991-10-04 Timothy J. Gregory Hiv envelope polypeptides
CA2078546A1 (en) * 1990-04-03 1991-10-04 Phillip W. Berman Methods and compositions for vaccination against hiv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides

Also Published As

Publication number Publication date
WO1998001564A1 (en) 1998-01-15
AU727107B2 (en) 2000-11-30
AP9901432A0 (en) 1999-03-31
JP2000515368A (ja) 2000-11-21
EP0942988A1 (en) 1999-09-22
AU3567797A (en) 1998-02-02
CA2259965A1 (en) 1998-01-15
OA10954A (en) 2001-10-25
TWI221846B (en) 2004-10-11
NZ333500A (en) 2000-09-29
IL127701A0 (en) 1999-10-28
ID17767A (id) 1998-01-22
IL127701A (en) 2006-08-01
ZA975889B (en) 1998-02-23
US6090392A (en) 2000-07-18

Similar Documents

Publication Publication Date Title
AU727107B2 (en) Hiv envelope polypeptides and vaccine
Cho et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
US6806055B2 (en) HIV envelopolype peptides
US10946090B2 (en) Consensus/ancestral immunogens
Earl et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
Girard et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
Berman et al. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers
JP4749481B2 (ja) 弱毒化された非機能性vifタンパク質による免疫応答性誘導
Kim et al. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
Montefiori et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques
US6585979B1 (en) HIV envelope polypeptides and immunogenic composition
Chakrabarti et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
US8048431B2 (en) Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
Quinnan Jr et al. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells
WO1998041536A1 (en) Glycosylation deficient siv and hiv envelope glycoproteins
WO1998041536A9 (en) Glycosylation deficient siv and hiv envelope glycoproteins
US20100080818A1 (en) Expression and Characterization of HIV-1 Envelope Protein Associated with Broadly Cross Reactive Neutralizing Antibody Response
Biron et al. A Modern Biopharmaceutical to Treat AIDS–Challenges in Designing HIV Env Immunogens for Developing a Vaccine
US20080057492A1 (en) Interacting site for gp41 on gp120 of hiv-1
Pinter HIV Vaccines Based on Novel MULV-HIV Fusion Proteins.